-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Apertinib, a KIT/PDGFRA inhibitor developed by Blueprint Medicines, was approved by the FDA in the United States in January 2020 for the treatment of advanced GIST adult patients carrying PDGFRA exon 18 mutations, including PDGFRA D842V.
Cornerstone Pharmaceuticals has entered into exclusive cooperation and licensing with Blueprint Medicines, which has obtained exclusive development and commercialization of a number of drugs, including Apertinib, in Greater China.
Note: The original text has a limitation.